These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
551 related articles for article (PubMed ID: 15355905)
1. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905 [TBL] [Abstract][Full Text] [Related]
2. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590 [TBL] [Abstract][Full Text] [Related]
3. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979 [TBL] [Abstract][Full Text] [Related]
4. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973 [TBL] [Abstract][Full Text] [Related]
5. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526 [TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759 [TBL] [Abstract][Full Text] [Related]
7. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729 [TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046 [TBL] [Abstract][Full Text] [Related]
9. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946 [TBL] [Abstract][Full Text] [Related]
10. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer. Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189 [TBL] [Abstract][Full Text] [Related]
11. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study. Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247 [TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Cappelletti V; Celio L; Bajetta E; Allevi A; Longarini R; Miodini P; Villa R; Fabbri A; Mariani L; Giovanazzi R; Galante E; Greco M; Grazia Daidone M Endocr Relat Cancer; 2004 Dec; 11(4):761-70. PubMed ID: 15613450 [TBL] [Abstract][Full Text] [Related]
13. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156 [TBL] [Abstract][Full Text] [Related]
15. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892 [TBL] [Abstract][Full Text] [Related]
16. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466 [TBL] [Abstract][Full Text] [Related]
17. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P Breast J; 2005; 11(4):278-80. PubMed ID: 15982396 [TBL] [Abstract][Full Text] [Related]
18. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen. Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L Breast J; 2007; 13(4):337-45. PubMed ID: 17593037 [TBL] [Abstract][Full Text] [Related]
19. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. Mariotto AB; Feuer EJ; Harlan LC; Abrams J J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888 [TBL] [Abstract][Full Text] [Related]
20. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]